Healthcare AI investors focused on Rare & Genetic Disorders
Venture firms, family offices, accelerators, and corporate VCs with explicit thesis exposure to Rare & Genetic Disorders within healthcare AI. Includes lead investors, follow-on participants, and active angels.
This highly specialized field focuses on diagnostics and treatments for conditions affecting exceptionally small patient populations. Driven by the fact that roughly 80% of rare diseases have a genetic origin, this sub-vertical heavily relies on advanced gene therapies, CRISPR gene-editing technologies, and orphan drug regulatory incentives to combat severe, life-threatening diseases.
1
investor match
